E
STAB

Ergoteles’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Ergoteles’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,325
Closed -$2.3K – 2015
2022
Q4 		$2.3K Buy
+28,325
New +$3.59K ﹤0.01% 1396

Other funds holding STAB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TAM
Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

Ergoteles's STAB Position: Q1 2023 in Review

Ergoteles sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 28,325 shares — an estimated $2.3K sold.

Ergoteles first reported a position in STAB in Q4 2022 and held it in 1 quarter. The position peaked at $2.3K in Q4 2022. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

  • Ergoteles reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 28,325 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $2.3K.
  • Ergoteles first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Ergoteles's Statera Biopharma, Inc. Common Stock position peaked at $2.3K in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.